keyword
MENU ▼
Read by QxMD icon Read
search

RPLND for testicular cancer

keyword
https://www.readbyqxmd.com/read/29135122/the-role-of-the-multidisciplinary-team-in-the-decision-making-process-in-stage-one-testicular-cancer-retrospective-cohort-analysis
#1
Tomislav Omrcen, Andrija Katic, Eduard Vrdoljak
PURPOSE: To analyze the role of a multidisciplinary team (MDT) in the decision-making process in clinical stage one (CS I) testicular cancer (TC). METHODS: We retrospectively evaluated data on 115 consecutive patients with CS I TC (excluding stage IS) who were referred to the Department of Oncology, University Hospital of Split, Croatia, from 2003 to 2012. Fifty-six patients (48.7%) were referred between 2003 and 2007, before the introduction of the MDT and 59 patients (51...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29104087/long-term-survival-of-good-risk-germ-cell-tumor-patients-after-postchemotherapy-retroperitoneal-lymph-node-dissection-a-comparison-of-bep%C3%A2-%C3%A3-3-vs-ep%C3%A2-%C3%A3-4-and-treating-institution
#2
Clint Cary, Joseph M Jacob, Costantine Albany, Timothy A Masterson, Nasser H Hanna, Lawrence H Einhorn, Richard S Foster
BACKGROUND: Patients with International Germ Cell Cancer Collaborative Group (IGCCCG) good-risk testicular cancer might receive either 4 cycles of etoposide and cisplatin (EP × 4) or 3 cycles of bleomycin, etoposide, and cisplatin (BEP × 3). We sought to examine differences in survival after retroperitoneal lymph node dissection (PC-RPLND) between patients who received EP × 4 compared with BEP × 3. PATIENTS AND METHODS: The Indiana University Testis Cancer database was queried to identify IGCCCG good-risk PC-RPLND patients who received either EP × 4 or BEP × 3 induction chemotherapy...
October 16, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29026972/retroperitoneal-lymph-node-dissection-for-testicular-seminomas-population-based-practice-and-survival-outcomes
#3
Hiten D Patel, Gregory A Joice, Zeyad R Schwen, Alice Semerjian, Ridwan Alam, Arnav Srivastava, Mohamad E Allaf, Phillip M Pierorazio
PURPOSE: While retroperitoneal lymph node dissection (RPLND) is traditionally reserved for nonseminomatous germ cell tumors, recent efforts to reduce long-term toxicities of radiation and chemotherapy have turned attention to its application for testicular seminomas. Currently, RPLND is reserved for the post-chemotherapy for stage II testicular seminomas; we aimed to describe current utilization of RPNLD for testicular seminomas by stage and implications for survival. METHODS: A national sample of men diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminoma (1988-2013) was evaluated from SEER Program registries...
October 12, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29021655/robot-assisted-retroperitoneal-lymph-node-dissection-feasibility-and-outcome-in-postchemotherapy-residual-mass-in-testicular-cancer
#4
Amitabh Singh, Smaranjit Chatterjee, Prashant Bansal, Abhishek Bansal, Sudhir Rawal
INTRODUCTION: We aimed to evaluate the surgical feasibility, complication, and oncological outcome of robot-assisted retroperitoneal lymph node dissection (RA-RPLND) in patients of testicular tumor with postchemotherapy residual retroperitoneal mass. METHODS: A total of 13 patients underwent RA-RPLND between January 2012 and September 2016 at our institute. A study was started on December 2015, so data were collected retrospectively and prospectively regarding patient demography, tumor characteristics, surgical, pathological outcome, and oncological outcome...
October 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28935185/impact-of-hospital-case-volume-on-testicular-cancer-outcomes-and-practice-patterns
#5
Solomon L Woldu, Justin T Matulay, Timothy N Clinton, Nirmish Singla, Laura-Maria Krabbe, Ryan C Hutchinson, Arthur Sagalowsky, Yair Lotan, Vitaly Margulis, Aditya Bagrodia
BACKGROUND: Given the rarity of testicular germ cell tumors (TGCTs) and the complex aspects of management, we evaluate the effect of hospital TGCT case volume on overall survival outcomes and practice patterns. MATERIALS AND METHODS: The National Cancer Database was queried for patients diagnosed with seminoma or nonseminomatous germ cell tumor (NSGCT). Hospitals were classified by case volume as high (99th percentile, ≥26.1 cases annually), high-intermediate (95-99th percentile, 14...
September 18, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28325537/midline-extraperitoneal-approach-to-retroperitoneal-lymph-node-dissection-in-testicular-cancer-minimizing-surgical-morbidity
#6
Sumeet Syan-Bhanvadia, Soroush T Bazargani, Thomas G Clifford, Jie Cai, Gus Miranda, Siamak Daneshmand
BACKGROUND: Retroperitoneal lymph node dissection (RPLND) is an important component of the management of testicular germ cell tumor (GCT) but carries significant surgical morbidity. OBJECTIVE: To describe our experience with a midline extraperitoneal (EP) approach to RPLND for seminomatous and nonseminomatous GCT. DESIGN, SETTING, AND PARTICIPANTS: From 2010 to 2015, 122 consecutive patients underwent RPLND from a prospective database. Patients requiring aortic resection or retrocrural dissection or with intraperitoneal disease were excluded...
November 2017: European Urology
https://www.readbyqxmd.com/read/28296054/modified-retroperitoneal-lymph-node-dissection-for-post-chemotherapy-residual-tumour-a-long-term-update
#7
Jane S Cho, Hristos Z Kaimakliotis, Clint Cary, Timothy A Masterson, Stephen Beck, Richard Foster
OBJECTIVE: To update previously reported outcomes of modified-template post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in appropriately selected patients with metastatic non-seminomatous germ cell tumour (NSGCT), as our previous report was criticised for short follow-up and so we now provide a long-term update on this cohort. PATIENTS AND METHODS: In all, 100 patients with normal serum markers after cisplatin-based chemotherapy and residual retroperitoneal tumour underwent modified PC-RPLND between 1991 and 2004...
July 2017: BJU International
https://www.readbyqxmd.com/read/28150168/retroperitoneal-lymph-node-dissection-an-update-in-testicular-malignancies
#8
REVIEW
K Yadav
Management of testicular cancer has evolved through many breakthroughs. The decades of zeal to improve oncologic adequacy and to decrease morbidity has led to the current scientific knowledge of retroperitoneal lymph node dissection templates. Retroperitoneal lymph node dissection (RPLND) has potential for staging, prognostication and therapeutic importance in the management of testicular malignancy. RPLND has overcome limitations of current imaging which understage 30% of stage I disease and overstage 25-30% of stage II disease...
July 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27879966/andrological-complications-following-retroperitoneal-lymph-node-dissection-for-testicular-cancer
#9
REVIEW
Alessandro Crestani, Francesco Esperto, Marta Rossanese, Gianluca Giannarini, Nicola Nicolai, Vincenzo Ficarra
Retroperitoneal lymph node dissection (RPLND) is a fundamental surgical step in the treatment of testicular cancer. Nowadays, primary RPLND has partially lost its role in favour of active surveillance (for low risk stage I disease) and short cycle chemotherapy in non-seminomatous germ cell tumor (NSGCT). Conversely, post-chemotherapy RPLND (PC-RPLND) remains the standard treatment for residual masses after chemotherapy. In consideration of curability rate of testicular cancer and the life expectancy of testicular cancer survivors the identification and the prevention of andrological complications became fundamental...
June 2017: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/27859263/post-chemotherapy-retroperitoneal-teratoma-in-nonseminomatous-germ-cell-tumors-do-predictive-factors-exist-results-from-a-national-multicenter-study
#10
MULTICENTER STUDY
Marie Dusaud, Bernard Malavaud, Younes Bayoud, Philippe Sebe, Jean Luc Hoepffner, Laurent Salomon, Alain Houlgatte, Géraldine Pignot, Jérome Rigaud, Aude Fléchon, Christian Pfister, Morgan Rouprêt, Michel Soulié, Arnaud Méjean, Xavier Durand
BACKGROUND AND OBJECTIVES: To identify predictive preoperative factors of the presence of teratoma in retroperitoneal lymph node dissection specimens. METHODS: We performed a 20 years multicenter retrospective analysis of all patients who underwent retroperitoneal lymph node dissection for residual masses after chemotherapy (PC-RPLND). Patients had undergone PC-RPLND after chemotherapy for advanced testicular cancer. The histologic components of the primary tumor were compared with those of the residual masses using logistic regression...
December 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27831507/surgical-management-of-complex-residual-masses-following-systemic-chemotherapy-for-metastatic-testicular-germ-cell-tumours
#11
A Heidenreich, F Haidl, P Paffenholz, Ch Pape, U Neumann, D Pfister
Background: Post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND) represents the treatment of choice in patients with residual masses following chemotherapy for metastatic germ cell tumours. Involvement of major retroperitoneal vessels or thoracic/lumbar spine is rare and challenging but needs complete resection for curative intent. We report on our experience in the management of such complex cases. Patients and methods: A total of 185 patients underwent PC-RPLND and we identified 25 (13...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27618772/management-of-stage-i-testicular-germ-cell-tumours
#12
REVIEW
Michal Chovanec, Nasser Hanna, K Clint Cary, Lawrence Einhorn, Costantine Albany
Clinical stage I testicular germ cell tumours (TGCT) are highly curable neoplasms. The treatment of stage I testicular cancer is complex and requires a multidisciplinary approach. Standard options after radical orchiectomy for seminoma include active surveillance, radiation therapy or 1-2 cycles of carboplatin, and options for nonseminoma include active surveillance, retroperitoneal lymph node dissection (RPLND) or 1-2 cycles of bleomycin plus etoposide plus cisplatin (BEP). All the options should be discussed with each patient and treatment choices should be made by shared decision making as virtually all patients with clinical stage I TGCT can be cured of their disease...
November 2016: Nature Reviews. Urology
https://www.readbyqxmd.com/read/27460844/post-chemotherapy-robotic-bilateral-retroperitoneal-lymph-node-dissection-using-a-novel-single-dock-technique
#13
Thomas E Stout, Samit D Soni, Alvin C Goh
There have been no previous reports of post-chemotherapy robotic bilateral retroperitoneal lymph node dissection (RPLND) using a single-dock technique. One deterrent of robotic RPLND is that accessing bilateral retroperitoneal spaces requires patient reposition and surgical robot redocking, therefore increasing operative time. Herein we provide the first step-by-step description of a single-dock technique for robotic bilateral RPLND in the post-chemotherapy setting. We describe port placement and technique for robot positioning to optimize access to bilateral retroperitoneal spaces with a single dock...
December 2016: Journal of Robotic Surgery
https://www.readbyqxmd.com/read/27372281/utilization-of-retroperitoneal-lymph-node-dissection-for-testicular-cancer-in-the-united-states-results-from-the-national-cancer-database-1998-2011
#14
Cory M Hugen, Brian Hu, Claudio Jeldres, Claire Burton, Craig R Nichols, Christopher R Porter, Siamak Daneshmand
INTRODUCTION: Retroperitoneal lymph node dissection (RPLND) for the treatment of testicular cancer is a relatively rare and complex operation that may contribute to differences in utilization. We sought to characterize the use of RPLND between different categories of cancer center facilities in the United States. MATERIALS AND METHODS: The National Cancer Database was queried for patients with germ cell tumors treated at different types of cancer centers between 1998 and 2011...
November 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27235751/pelvic-lymph-node-dissection-in-patients-treated-for-testis-cancer-the-memorial-sloan-kettering-cancer-center-experience
#15
Shaheen R Alanee, Brett S Carver, Darren R Feldman, Robert J Motzer, George J Bosl, Joel Sheinfeld
OBJECTIVE: To describe the pathologic findings and clinical outcome data for patients undergoing pelvic lymph node dissection (PLND) in the course of management of testicular germ cell tumors at Memorial Sloan Kettering Cancer Center (MSKCC). PATIENTS AND METHODS: Following institutional review board approval, data on 2186 patients who underwent retroperitoneal lymph node dissection (RPLND) at MSKCC between 1989 and 2011 were retrospectively reviewed. Of these 2186 patients, we analyzed data for 44 patients (2%) who underwent PLND at the time of RPLND...
September 2016: Urology
https://www.readbyqxmd.com/read/27234998/safety-and-early-oncologic-effectiveness-of-primary-robotic-retroperitoneal-lymph-node-dissection-for-nonseminomatous-germ-cell-testicular-cancer
#16
Shane M Pearce, Shay Golan, Michael A Gorin, Amy N Luckenbaugh, Stephen B Williams, John F Ward, Jeffrey S Montgomery, Khaled S Hafez, Alon Z Weizer, Phillip M Pierorazio, Mohamad E Allaf, Scott E Eggener
BACKGROUND: Primary robot-assisted retroperitoneal lymph node dissection (R-RPLND) has been studied as an alternative to open RPLND in single-institution series for patients with low-stage nonseminomatous germ cell tumors (NSGCT). OBJECTIVE: To evaluate a multicenter series of primary R-RPLND for low-stage NSGCT. DESIGN, SETTING, AND PARTICIPANTS: Between 2011 and 2015, 47 patients underwent primary R-RPLND at four centers for Clinical Stage (CS) I-IIA NSGCT...
March 2017: European Urology
https://www.readbyqxmd.com/read/27169016/development-of-cns-type-primitive-neuroectodermal-tumor-in-metastatic-testicular-mixed-germ-cell-tumor
#17
Anobel Y Odisho, Joseph T Rabban, Maxwell V Meng
A 29-year-old man presenting with a retroperitoneal mass was found to have a testis lesion consistent with mixed germ cell tumor and the RPLND specimen showed teratoma with an area of central nervous system-type primitive neuroectodermal tumor (PNET) not present in the testis. Whether such primitive tumor components represent a de novo tumor component or represent progression from existing neuroepithelial teratomatous elements is unclear. Given the high likelihood of residual tumor and possibility of malignant transformation, post-chemotherapy RPLND remains vital in treating patients with testis cancer...
May 2016: Urology Case Reports
https://www.readbyqxmd.com/read/27068395/robot-assisted-laparoscopic-retroperitoneal-lymph-node-dissection-for-testicular-cancer-evolution-of-the-technique
#18
Sevan Stepanian, Mayank Patel, James Porter
BACKGROUND: Retroperitoneal lymph node dissection (RPLND) is an accepted staging and treatment option for nonseminomatous germ cell tumor. Robotic surgery offers technical advantages and is being increasingly used in urologic procedures. OBJECTIVE: To determine the feasibility and safety of robotic surgery for RPLND. DESIGN, SETTING, AND PARTICIPANTS: A retrospective review of robotic (R)-RPLND performed by a single surgeon from April 2008 to October 2014 using two approaches was performed...
October 2016: European Urology
https://www.readbyqxmd.com/read/26968421/robotic-primary-rplnd-for-stage-i-testicular-cancer-a-review-of-indications-and-outcomes
#19
REVIEW
Heather J Chalfin, Wesley Ludwig, Phillip M Pierorazio, Mohamad E Allaf
Patients diagnosed with stage I non-seminomatous germ cell tumor (NSGCT) face the task of selecting a management strategy. Whereas these options all offer excellent survival, unfortunately, each has drawbacks. Retroperitoneal lymph node dissection (RPLND) is a major operation with low, but significant risks of bleeding, chylous ascites, and retrograde ejaculation. Platinum-based chemotherapy is associated with a number of long-term side effects, not all of which are quantified, but include secondary malignancy and early cardiovascular disease...
May 2016: Current Urology Reports
https://www.readbyqxmd.com/read/26820659/-postchemotherapy-residual-tumour-resection-in-complex-metastatic-sites-of-advanced-testicular-germ-cell-tumours
#20
P Paffenholz, D Pfister, A Heidenreich
INTRODUCTION: Postchemotherapy residual tumour resection (PC-RTR) is an integral part of the multimodal therapy for advanced testicular germ cell tumours. Depending on the extent and localisation of the residual mass, PC-RTR may necessitate a multidisciplinary procedure (which should be planned preoperatively), to resolve even complex situations in an oncologically sound manner, with lower treatment-related morbidity The aim of article is to report on the interdisciplinary management of complex residual masses...
May 2016: Der Urologe. Ausg. A
keyword
keyword
10161
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"